Kamada (NASDAQ:KMDA) Stock Passes Below Two Hundred Day Moving Average of $5.45

Kamada Ltd. (NASDAQ:KMDA) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.45 and traded as low as $5.26. Kamada shares last traded at $5.31, with a volume of 57,951 shares traded.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. StockNews.com downgraded shares of Kamada from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 27th. Stifel Nicolaus started coverage on shares of Kamada in a research report on Wednesday, July 3rd. They issued a “buy” rating and a $18.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Kamada in a research report on Thursday, August 15th.

Kamada Stock Down 0.9 %

The company’s fifty day moving average is $5.56 and its 200 day moving average is $5.45. The firm has a market cap of $305.22 million, a price-to-earnings ratio of 23.09 and a beta of 1.07.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The firm had revenue of $42.47 million during the quarter, compared to analysts’ expectations of $39.70 million. Kamada had a net margin of 9.75% and a return on equity of 6.15%. On average, equities research analysts forecast that Kamada Ltd. will post 0.26 EPS for the current fiscal year.

Hedge Funds Weigh In On Kamada

Several hedge funds have recently bought and sold shares of the company. Aristides Capital LLC lifted its position in shares of Kamada by 41.6% in the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 16,635 shares during the period. Y.D. More Investments Ltd increased its stake in Kamada by 1,956.0% during the 2nd quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock valued at $3,643,000 after purchasing an additional 690,842 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Kamada by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after acquiring an additional 100,800 shares during the last quarter. 20.38% of the stock is owned by institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.